Across TCGA pan-cancer cohorts, FAM47A mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM47A data layer compared with 14 for mass-spec protein and 8 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FAM47A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FAM47A expression acts as an unfavorable survival marker.
LUAD are the cancer types where FAM47A mass-spec protein most reproducibly stratifies survival.